Bayer AG proposes $10.5B settlement package to resolve Roundup U.S. cancer lawsuits

Bayer moves to cap Roundup litigation with $10.5 billion settlement package

Bayer AG announces a proposed $10.5 billion package to resolve current and future U.S. lawsuits that allege its Roundup weedkiller causes non-Hodgkin's lymphoma. The company outlines a $7.5 billion class-action framework to be lodged through cases in Missouri state court that would cover suits already filed and potential claims over a 20-year period, alongside a separate $3 billion resolution for existing U.S. cases in which plaintiffs attribute cancers to Roundup use.

The company says the combined proposal is designed to complement its ongoing Supreme Court appeal and to narrow legal uncertainty. Chief Executive Bill Anderson states, "We are entering into the settlement because it is an important addition to the case before the Supreme Court, thereby minimising the legal risks as comprehensively as possible," and adds that "Both elements are necessary independently of each other and reinforce each other." Bayer frames the class component as an important legal tool to address both present claims and long-term exposure.

The move builds on prior legal payouts. Bayer has previously paid about $10 billion to settle most Roundup lawsuits pending as of 2020 but has not succeeded in reaching a deal that covers future filings, and new lawsuits continue to be filed. Plaintiffs across the U.S. say they developed non-Hodgkin's lymphoma and other cancers after using Roundup at home or at work; the herbicide, acquired by Bayer in its purchase of Monsanto, remains among the most widely used weedkillers in the United States.

Plaintiffs’ counsel point to remaining uncertainties and variable outcomes. Lawyers representing claimants caution that even with a class structure and case resolutions, individual case outcomes may still differ by jurisdiction and timeframe, leaving some claimants and courts to negotiate separate terms and timetables.

Analysts and industry observers say the proposed resolution could materially lower Bayer’s contingent liabilities and allow management to focus on operations and research. The plan, if approved, is likely to affect how major agrochemical companies structure long-term liability provisions and handle legacy product litigation while maintaining commercial availability of commonly used herbicides.